Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: BioInformant | PRODUCT CODE: 1443436

Cover Image

PUBLISHER: BioInformant | PRODUCT CODE: 1443436

CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024

PUBLISHED:
PAGES: 207 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 1997
PDF (Site License)
USD 2097
PDF (Global License)
USD 2197

Add to Cart

Description

Table of Contents

EXECUTIVE SUMMARY:

CAR-T industry funding isn't gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti have reached the marketplace and created a funding boom. In recent years, CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, which account for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their terms, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.

Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these CAR-T companies to invest in their infrastructure and product pipelines. During the same period, CAR-T companies raised an impressive $5.8 billion through IPO funding to strengthen their technology platforms, clinical trial programs, and corporate efforts.

Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners. Thus, the total value of CAR-T licensing deals over the past decade accounts for another $3.9 billion in transactions and this total is expected to expand substantially in the coming decade.

Among the various financing types analyzed in this report-which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, co-development agreements, and M&A deals-M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.

For the nascent CAR-T industry, it is a phenomenal achievement to raise more than $128.25 billion through these various deals that have reported their financial terms. Additionally, 59 of 84 CAR-T licensing deals, 65 of the 98 CAR-T collaboration deals, and 11 of the 27 CAR-T industry M&A deals did not disclose the value of their transactions. Thus, if an approximate estimate is calculated for all deals of undisclosed values, the total value would be a staggering $240 billion.

At present, six CAR-T therapies have been approved by U.S. FDA, including:

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexucabtagene autoleucel (Tecartus)
  • Lisocabtagene maraleucel (Breyanzi)
  • Idecabtagene vicleucel (Abecma)
  • Ciltacabtagene autoleucel (Carvykte)

Many of the CAR-T therapies above have been approved by other regulatory agencies, most commonly for use within the EU. Numerous CAR-T therapies have reached commercialization in other regions as well, such as Relma-cel's (Relmacabtagene) and Yikaida's (Axicabtagene ciloleucel) approval from the NMPA in China, Ebvallo's (tabelecleucel) approval from the European Commission, Actaly-cel's (Actalycabtagene autoleucel) in India, and Fucaso's (Equecabtagene autoleucel) approval in China, for example. This list is not exhaustive because CAR-T approvals are accelerating on a global scale. According to ClinicalTrials.gov, there are also an incredible 706 CAR-T programs that are in clinical phases of development.

This CAR-T market funding report summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events. Of course, it aggregates these numbers so you can understand the global impact of these funding events and how they are propelling rapid growth of the CAR-T sector at large.

It features the following information for the CAR-T cell therapy industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • Co-Development Agreements
  • M&A Transactions
  • Companies Profiles for CAR-T Market Competitors

You can use it to:

  • 1. Quantify CAR-T industry investments
  • 2. Identify well-capitalized companies
  • 3. Scout potential partnerships and alliances
  • 4. Understand partnerships and co-development programs for CAR-T technologies
  • 5. Identify M&A activity within the CAR-T industry

In summary, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

Show more

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. GLOBAL COMMERCIALIZATION OF CAR-T CELL THERAPIES

  • 2.1. Total Number of Patients Treated with CAR-T Cell Therapies by Year, 2017-2023
  • 2.2. Total Sales Revenues Generated by FDA-Approved CAR-T Therapies, 2017-2023
  • 2.3. List Prices of FDA-Approved CAR-T Therapies

3. CAR-T INDUSTRY FUNDING EVENTS

  • 3.1. CAR-T Industry Venture Capital Financing Events
    • 3.1.1. Total Venture Capital Raised by CAR-T Companies, 2014 - 2023
    • 3.1.2. Year-Over-Year Comparison of Venture Capital Funding Raised by CAR-T Companies
    • 3.1.3. Venture Capital Raised by CAR-T Companies (78 Capital Raises) - Deal Terms & Values
      • 3.1.3.1. Bellicum Pharmaceuticals
      • 3.1.3.2. CRISPR Therapeutics
      • 3.1.3.3. Autolus
      • 3.1.3.4. Cellular Biomedicine Group
      • 3.1.3.5. Adicet Bio
      • 3.1.3.6. Autolus Limited
      • 3.1.3.7. Cellular Biomedicine Group
      • 3.1.3.8. JW Therapeutics
      • 3.1.3.9. Carina Biotech
      • 3.1.3.10. PeproMene Bio
      • 3.1.3.11. Precision BioSciences
      • 3.1.3.12. Cabaletta Bio
      • 3.1.3.13. Vor Biopharma
      • 3.1.3.14. Gracel Biotechnologies
      • 3.1.3.15. Mustang Bio
      • 3.1.3.16. Poseida Therapeutics
      • 3.1.3.17. BioNTech
      • 3.1.3.18. Adicet Bio
      • 3.1.3.19. Kyverna Therapeutics
      • 3.1.3.20. EXUMA Biotech
      • 3.1.3.21. IASO Biotherapeutics
      • 3.1.3.22. Legend Biotech
      • 3.1.3.23. JW Therapeutics
      • 3.1.3.24. Vor Pharma
      • 3.1.3.25. ImmPACT Bio
      • 3.1.3.26. Synthekine
      • 3.1.3.27. Gracell Biotechnologies
      • 3.1.3.28. CARsgen Therapeutics
      • 3.1.3.29. Umoja Biopharema
      • 3.1.3.30. Juventas Cell Therapy
      • 3.1.3.31. Celyad Oncology
      • 3.1.3.32. Artiva Biotherapeutics
      • 3.1.3.33. Caribou Biosciences
      • 3.1.3.34. Biosceptre
      • 3.1.3.35. Noile-Immune Biotech
      • 3.1.3.36. Arcellx
      • 3.1.3.37. Cellares Corporation
      • 3.1.3.38. Interius BioTherapeutics
      • 3.1.3.39. Synthekine
      • 3.1.3.40. Umoja Biopharma
      • 3.1.3.41. Wugen
      • 3.1.3.42. Mnemo Therapeutics
      • 3.1.3.43. AvenCell
      • 3.1.3.44. Currus Biologics
      • 3.1.3.45. Juventas Cell Therapy
      • 3.1.3.46. Carina Biotech
      • 3.1.3.47. IASO Biotherapeutics
      • 3.1.3.48. Cellular Biomedicines
      • 3.1.3.49. AffyImmune Therapeutics
      • 3.1.3.50. Leucid Bio
      • 3.1.3.51. Clade Therapeutics
      • 3.1.3.52. SOTIO Biotech
      • 3.1.3.53. EXUMA Biotech
      • 3.1.3.54. ImmPACT Bio
      • 3.1.3.55. Kyverna Therapeutics
      • 3.1.3.56. Ucello Therapeutics
      • 3.1.3.57. Mustang Bio
      • 3.1.3.58. Wugen
      • 3.1.3.59. Inceptor Bio
      • 3.1.3.60. Tessa Therapeutics
      • 3.1.3.61. Immuneel Therapeutics
      • 3.1.3.62. OriCell Therapeutics
      • 3.1.3.63. Carina Biotech
      • 3.1.3.64. Juventas Cell Therapy
      • 3.1.3.65. Arsenal Biosciences
      • 3.1.3.66. Synthekine
      • 3.1.3.67. IASO Biotherapeutics
      • 3.1.3.68. MPC Therapeutics
      • 3.1.3.69. OriCell Therapeutics
      • 3.1.3.70. Verismo Therapeutics
      • 3.1.3.71. Cargo Therapeutics
      • 3.1.3.72. OneChain Immunotherapeutics
      • 3.1.3.73. Caribou Biosciences
      • 3.1.3.74. Verismo Therapeutics
      • 3.1.3.75. Kyverna Therapeutics
      • 3.1.3.76. Gracell Biotechnologies
      • 3.1.3.77. Cellares
      • 3.1.3.78. Celyad Oncology

4. IPO FUNDING RAISED BY CAR-T CELL THERAPY COMPANIES

  • 4.1. IPO Funds Raised by CAR-T Compamies - Deal Terms & Values
    • 4.1.1. Juno Therapeutics
    • 4.1.2. Cellular Biomedicine Group
    • 4.1.3. Xenetic Biosciences
    • 4.1.4. Cellular Biomedicine Group
    • 4.1.5. Autolus Therapeutics
    • 4.1.6. Allogene Therapeutics
    • 4.1.7. Precision BioSciences
    • 4.1.8. Atara Biotherapeutics
    • 4.1.9. Xenetic Biosciences
    • 4.1.10. Cabaletta Bio
    • 4.1.11. Atara Biotherapeutics
    • 4.1.12. Legend Biotech
    • 4.1.13. Mustang Bio
    • 4.1.14. JW Therapeutics
    • 4.1.15. Atara Biotherapeutics
    • 4.1.16. Gracell Biotechnologies
    • 4.1.17. Vor Biopharma
    • 4.1.18. Adicet Bio
    • 4.1.19. CARsgen Therapeutics
    • 4.1.20. Xenetic Biosciences
    • 4.1.21. Caribou Biosciences
    • 4.1.22. Celyad Oncology
    • 4.1.23. Adicet Bio
    • 4.1.24. Legend Biotech
    • 4.1.25. Kyverna Therapeutics
    • 4.1.26. Arcellx
    • 4.1.27. TC Biopharm
    • 4.1.28. Celularity
    • 4.1.29. TC BioPharm
    • 4.1.30. Precision Biosciences
    • 4.1.31. Legend Biotech
    • 4.1.32. TC Biopharm
    • 4.1.33. Vor Biopharma
    • 4.1.34. Precigen
    • 4.1.35. TC Biopharm
    • 4.1.36. Celularity
    • 4.1.37. Legend Biotech
    • 4.1.38. Coeptis Therapeutics
    • 4.1.39. Caribou Biosciences

5. CAR-T LICENSING DEALS EXECUTED GLOBALLY

  • 5.1. Total Value of CAR-T Licensing Deals Worldwide
    • 5.1.1. Descriptions of CAR-T Licensing Deals - Deal Terms & Values
      • 5.1.1.1. Cellectis & Ohio State University
      • 5.1.1.2. bluebird bio & Five Prime Therapeutics
      • 5.1.1.3. Poseida Therapeutics & Janssen Biotech
      • 5.1.1.4. bluebird bio & ViroMed
      • 5.1.1.5. Bellicum Pharmaceuticals & Astellas Pharma
      • 5.1.1.6. CRISPR Therapeutics & MaxCyte
      • 5.1.1.7. bluebird bio & Novartis
      • 5.1.1.8. Novartis & Celyad
      • 5.1.1.9. TC Biopharm & University College London (UCL)
      • 5.1.1.10. Mustang Bio & Fred Hutchinson Cancer Research Center
      • 5.1.1.11. Mustang Bio & Harvard University
      • 5.1.1.12. bluebird bio & TC Biopharm
      • 5.1.1.13. Janssen Biotech & Legend Biotech
      • 5.1.1.14. Autolus & UCL Business
      • 5.1.1.15. Otsuka Pharmaceutical & Osaka University
      • 5.1.1.16. Cellular Biomedicine & Novartis
      • 5.1.1.17. CRISPR Therapeutics & MaxCyte
      • 5.1.1.18. Wugen & Washington University
      • 5.1.1.19. Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center
      • 5.1.1.20. bluebird bio & Inhibrx
      • 5.1.1.21. Autolus Therapeutics & Noile-Immune Biotech
      • 5.1.1.22. Vor Biopharma & MaxCyte
      • 5.1.1.23. Juno Therapeutics & Oxford Biomedica
      • 5.1.1.24. Allogene Therapeutics & MaxCyte
      • 5.1.1.25. Kite & Teneobio
      • 5.1.1.26. Legend Biotech & Noile-Immune Biotech
      • 5.1.1.27. Caribou Biosciences & MaxCyte
      • 5.1.1.28. Prescient Therapeutics & University of Pennsylvania
      • 5.1.1.29. Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center
      • 5.1.1.30. Luminary Therapeutics & Case Western Reserve University
      • 5.1.1.31. Beam Therapeutics & Oxford Biomedica
      • 5.1.1.32. SOTIO Biotech & Unum Therapeutics
      • 5.1.1.33. Vor Biopharma & Metagenomi
      • 5.1.1.34. Chimeric Therapeutics & City of Hope
      • 5.1.1.35. Vor Biopharma & Arbor Biotechnologies
      • 5.1.1.36. Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)
      • 5.1.1.37. Vor Biopharma & National Cancer Institute (NCI)
      • 5.1.1.38. Caribou Biosciences & Memorial Sloan Kettering Cancer Center
      • 5.1.1.39. Carina Biotech & Bionomics
      • 5.1.1.40. Atara Biotherapeutics & Bayer
      • 5.1.1.41. Cellectis & SIRION Biotech
      • 5.1.1.42. Eli Lilly & Precision BioSciences
      • 5.1.1.43. AbbVie & Caribou Biosciences
      • 5.1.1.44. Luminary Therapeutics & Bio-Techne Corporation
      • 5.1.1.45. Wugen & HCW Biologics
      • 5.1.1.46. Alpha Biopharma & Wugen
      • 5.1.1.47. Servier & Precision Biosciences
      • 5.1.1.48. Dr. Reddy's Laboratories & Pregene Biopharma
      • 5.1.1.49. Celularity & MaxCyte
      • 5.1.1.50. BioNTech & Takara Bio
      • 5.1.1.51. Bellicum Pharmaceuticals & UNC Lineberger
      • 5.1.1.52. Mustang Bio & Mayo Clinic
      • 5.1.1.53. Precision Biosciences & Tiziana Sciences
      • 5.1.1.54. Arcellx & Oxford Biomedica
      • 5.1.1.55. Carina Biotech & BayPAT
      • 5.1.1.56. Inceptor Bio & University of California
      • 5.1.1.57. Rebirthel & Otsuka Pharmaceutical
      • 5.1.1.58. Kyverna Therapeutics & National Institutes of Health (NIH)
      • 5.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 5.1.1.60. Antion Biosciences & Allogene Therapeutics
      • 5.1.1.61. Sana Biotechnology & IASO Biotherapeutics
      • 5.1.1.62. CellPoint & Pregene
      • 5.1.1.63. Xenetic Biosciences
      • 5.1.1.64. GO Therapeutics
      • 5.1.1.65. LG Chem & MaxCyte
      • 5.1.1.66. Roche & Poseida Therapeutics
      • 5.1.1.67. Chugai Pharmaceutical & Noile-Immune Biotech
      • 5.1.1.68. Beam Therapeutics & Orbital Therapeutics
      • 5.1.1.69. Undisclosed Company & Oxford Biomedica
      • 5.1.1.70. Coeptis Therapeutics & University of Pittsburgh
      • 5.1.1.71. Cabaletta Bio & IASO Biotherapeutics
      • 5.1.1.72. Inceptor Bio & Avectas
      • 5.1.1.73. Kite Pharma & Refuge Biotechnologies
      • 5.1.1.74. Kite Pharma & Arcellx
      • 5.1.1.75. Cabaletta Bio & Autolus Therapeutics
      • 5.1.1.76. Precigen & Alaunos
      • 5.1.1.77. Leucid Bio & ImaginAb
      • 5.1.1.78. Affini-T Therapeutics & MSK
      • 5.1.1.79. Shunxi Holding & Cartherics
      • 5.1.1.80. Janssen Biotech & Cellular Biomedicine
      • 5.1.1.81. Astellas Pharma & Poseida Therapeutics
      • 5.1.1.82. Imugene & Precision Biosciences
      • 5.1.1.83. Cabaleta Bio & Oxford Biomedica
      • 5.1.1.84. Kyverna Therapeutics & Oxford Biomedica
      • 5.1.1.85. Coeptis Therapeutics & Univerdity of Pittsburgh

6. CAR-T COLLABORATION DEALS

  • 6.1. CAR-T Collaboration Deals between 2013 and 2023
    • 6.1.1. Descriptions of CAR-T Collaboration Deals Signed 2013 to 2023
      • 6.1.1.1. bluebird Bio & Celgene Corporation
      • 6.1.1.2. Pfizer, Inc. & Cellectis
      • 6.1.1.3. Amgen & Kite Pharma
      • 6.1.1.4. Five Prime Therapeutics & bluebird bio
      • 6.1.1.5. Celgene & Juno Therapeutics
      • 6.1.1.6. Cellectis & Servier
      • 6.1.1.7. Kite Pharma & Cell Design Labs
      • 6.1.1.8. Kite Pharma & Fosun Pharma
      • 6.1.1.9. Cellular Biomedicine Group & GE Healthcare Life Sciences, China
      • 6.1.1.10. Novartis & bluebird bio & Celyad
      • 6.1.1.11. Mustang Bio & Harvard University & Beth Israel Deaconess Medical
      • 6.1.1.12. Jenssen Biotech & Legend Biotech
      • 6.1.1.13. PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec
      • 6.1.1.14. Kite Pharma & Sangamo Therapeutics
      • 6.1.1.15. bluebird bio & Celgene Corporation
      • 6.1.1.16. AbbVie & Calibr
      • 6.1.1.17. Novartis & Fraunhofer IZI
      • 6.1.1.18. Cellular Biomedicine & Novartis
      • 6.1.1.19. Regeneron Pharmaceuticals & bluebird bio
      • 6.1.1.20. Cartherics & ToolGen
      • 6.1.1.21. TC Biopharm & Dublin's Trinity College
      • 6.1.1.22. MaxCyte & Kite Pharma
      • 6.1.1.23. Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite
      • 6.1.1.24. Cellectis SA & Servier Monde
      • 6.1.1.25. MaxCyte & Allogene Therapeutics
      • 6.1.1.26. Fate Therapeutics & Janssen Biotech
      • 6.1.1.27. bluebird bio & Bristol Myers Squibb
      • 6.1.1.28. Xenetic Biosciences & PJSC Pharmsynthez
      • 6.1.1.29. Fate Therapeutics & Baylor College of Medicine
      • 6.1.1.30. Beam Therapeutics & Oxford Biomedica
      • 6.1.1.31. Carina Biotech & Glytherix
      • 6.1.1.32. Chimeric Therapeutics & City of Hope
      • 6.1.1.33. Biosceptre & Carina Biotech
      • 6.1.1.34. Allogene Therapeutics & University of Texas MD Anderson Center
      • 6.1.1.35. Oxford Biomedica & PhoreMost Limited
      • 6.1.1.36. Carina Biotech & Bionomics
      • 6.1.1.37. Bayer AG & Atara Biotherapeutics
      • 6.1.1.38. Oncternal Therapeutics & Karolinska Instituet
      • 6.1.1.39. EXUMA Biotech & Moffitt Cancer Center
      • 6.1.1.40. AbbVie & Caribou Biosciences
      • 6.1.1.41. Cytovia Therapeutics & Cellectis SAS
      • 6.1.1.42. JW Therapeutics & Thermo Fisher Scientific
      • 6.1.1.43. AbbVie & Caribou Biosciences
      • 6.1.1.44. Wugen & Alpha Biopharma
      • 6.1.1.45. Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma
      • 6.1.1.46. Vor Biopharma & Abound Bio
      • 6.1.1.47. Kite Pharma & Fosun Pharmaceutical
      • 6.1.1.48. Takara Bio & BioNTech
      • 6.1.1.49. Vor Biopharma & Janssen Biotech
      • 6.1.1.50. Imugene & Celularity
      • 6.1.1.51. Gracell Biotechnologies & FutureGen Biopharm
      • 6.1.1.52. AdAlta & Carina Biotech
      • 6.1.1.53. Celularity & Oncternal Therapeutics
      • 6.1.1.54. Autolus Therapeutics & Blackstone Life Sciences
      • 6.1.1.55. 4basebio & Leucid Bio
      • 6.1.1.56. Leucid Bio & Lonza
      • 6.1.1.57. Oxford Biomedica & Arcellx
      • 6.1.1.58. Carina Biotech & Bayerische Patentallianz (BayPAT)
      • 6.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 6.1.1.60. Arsenal Biosciences & Bristol Myers Squibb
      • 6.1.1.61. Allogene Therapeutics & Antion Biosciences
      • 6.1.1.62. Transgene & PersonGen BioTherapeutics
      • 6.1.1.63. Immatics & Bristol Myers Squibb
      • 6.1.1.64. Legend Biotech & Janssen Biotech
      • 6.1.1.65. Umoja Biopharma & Lupagen
      • 6.1.1.66. Immatics & Celgene
      • 6.1.1.67. Immatics & Bristol Myers Squibb
      • 6.1.1.68. Umoja Biopharma & TreeFrog Therapeutics
      • 6.1.1.69. Invectys & University of Texas Cancer Center
      • 6.1.1.70. Poseida Therapeutics & Roche
      • 6.1.1.71. Chugai Pharmaceutical & Noile-Immune Biotech
      • 6.1.1.72. Kite Pharma & Arcellx
      • 6.1.1.73. Arsenal Biosciences & Genentech
      • 6.1.1.74. Autolus Therapeutics & Bristol Myers Squibb
      • 6.1.1.75. Inceptor Bio & Avectos
      • 6.1.1.76. JW Therapeutics & 2seventy bio
      • 6.1.1.77. Peter MacCallum Cancer Centre and Cartherics
      • 6.1.1.78. Umoja Biopharma & IASO Biotherapeutics
      • 6.1.1.79. Kite Pharma & Arcellx
      • 6.1.1.80. Ori Biotech & Inceptor Bio
      • 6.1.1.81. Simnova & Orna Therapeutics
      • 6.1.1.82. CARsgen Therapeutics & Huadong Medicine
      • 6.1.1.83. TC Biopharm & University of Texas MD Anderson Cancer Center
      • 6.1.1.84. Kite Pharma & Arcellx
      • 6.1.1.85. Peter MacCallum Cancer Centre & Cartherics
      • 6.1.1.86. Cartherics & Shunxi Holding Group
      • 6.1.1.87. Autolus Therapeutics & Cardinal Health
      • 6.1.1.88. Cartherics & Shunxi
      • 6.1.1.89. Janssen Biotech & Cellular Biomedicine
      • 6.1.1.90. CytoMed Therapeutics & University of Texas MD Anderson Cancer
      • 6.1.1.91. Noile-Immune Biotech & Sysmex
      • 6.1.1.92. GenScript Biotech & T-MAXIMUM Biotech
      • 6.1.1.93. CytoMed Therapeutics & Hangzhou CNK Therapeutics
      • 6.1.1.94. CARsgen Therapeutics & Moderna
      • 6.1.1.95. Cellares & Bristol Myers Squibb
      • 6.1.1.96. Celularity & Regeneron Pharmaceuticals
      • 6.1.1.97. Verily & Kyverna Therapeutics
      • 6.1.1.98. Kyverna Therapeutics & Elevate Bio

7. CAR-T INDUSTRY M&A DEALS (MERGER AND ACQUISITION)

  • 7.1. Globally Executed M&A Deals within the CAR-T Cell Therapy Sector - Terms and Values
    • 7.1.1. Cellular Biomedicine & Chinese PLA General Hospital
    • 7.1.2. Gilead Sciences & Kite Pharma
    • 7.1.3. Gilead Sciences & Cell Design Labs
    • 7.1.4. Novartis & Endocyte
    • 7.1.5. Bristol Myers Squibb & Celgene
    • 7.1.6. Xenetic Biosciences & Scripps Research Institute
    • 7.1.7. Astellas Pharma & Xyphos Biosciences
    • 7.1.8. BioNTech & Neon Therapeutics
    • 7.1.9. resTORbio & Adicet Bio
    • 7.1.10. Century Therapeutics & Empirica Therapeutics
    • 7.1.11. Celularity & GX Acquisition
    • 7.1.12. Cellular Biomedicine & CBMG Merger Sub
    • 7.1.13. Amgen & Five Prime Therapeutics
    • 7.1.14. BioNTech & Kite
    • 7.1.15. ImmPACT Bio & Kalthera
    • 7.1.16. Kiromic Biopharma & InSilico Solutions
    • 7.1.17. Allogene Therapeutics & Antion Biosciences
    • 7.1.17. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.18. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.19. Galapagos & CellPoint/AboundBio
    • 7.1.20. Atossa Therapeutics & Dynamic Cell Therapies
    • 7.1.21. Kite & Tmunity Therapeutics
    • 7.1.22. Janssen & Cellular Biomedicine
    • 7.1.23. Mustang Bio & uBriGene Biosciences
    • 7.1.24. Precision Biosciences & Imugene
    • 7.1.25. Oxford Biomedica & Institut Merieux
    • 7.1.26. Clade Therapeutics & Gadeta
    • 7.1.27. Kyowa Kirin & Orchard Therapeutics

8. PROFILES OF CAR-T COMPANIES INVOLVED WITH FUNDING EVENTS

  • 8.1. AdAlta Ltd.
  • 8.2. Adicet Bio
    • 8.2.1. Gamma Delta T Cells
  • 8.3. AffyImmune Therapeutics, Inc.
    • 8.3.1. Affinity-Tuned CARs
    • 8.3.2. Real-Time CAR-T Cell Monitoring
  • 8.4. Allogene Therapeutics
    • 8.4.1. AlloCAR-T
  • 8.5. Alpha Biopharma
  • 8.6. Antion Biosciences
    • 8.6.1. miCAR-T Technology
  • 8.7. Arcellx, Inc.
    • 8.7.1. D-Domain Technology
    • 8.7.2. ddCAR
    • 8.7.3. ARC-SparX
  • 8.8. Arsenal Biosciences, Inc.
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Partnering
  • 8.10. Atara Biotherapeutics
  • 8.11. Autolus Therapeutics PLC
  • 8.12. AvenCell Therapeutics, Inc.
    • 8.12.1. Universal Switchable CAR Platform
  • 8.13. Beam Therapeutics
  • 8.14. Bellicum Pharmaceuticals, Inc.
    • 8.14.1. GoCAR Technology
    • 8.14.2. CaspaCIDe Technology
  • 8.15. Biosceptre
    • 8.15.1. The Unique Target: nfP2X7
  • 8.16. BioNTech SE
    • 8.16.1. Neoantigen-based T Cell Therapy Platform
  • 8.17. bluebird bio
  • 8.18. Cargo Therapeutics
  • 8.19. Caribou Biosciences, Inc.
    • 8.19.1. Next-Generation CRISR Technology
    • 8.19.1. CAR-T Therapy Platform
  • 8.20. Carina Biotech
    • 8.20.1. LGR5 CAR-T Program
  • 8.21. CARsgen Therapeutics Holdings Limited
    • 8.21.1. CycloCAR
    • 8.21.2. THANK-uCAR
  • 8.22. Cartherics Pty Ltd
    • 8.22.1. Cartherics' CAR-T Cells
  • 8.23. Cellares
    • 8.23.1. Cell Shuttle
  • 8.24. Cellectis
  • 8.25. Cellular Biomedicine Group
  • 8.26. Celularity, Inc.
    • 8.26.1. Power of the Placenta
    • 8.26.2. NK Cell Platform
    • 8.26.3. T Cell Platform
    • 8.26.4. Exosome Platform
  • 8.27. Celyad Oncology
    • 8.27.1. shRNA Platform
    • 8.27.2. shARC Platform
  • 8.28. Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • 8.29. Chimeric Therapeutics, Ltd.
    • 8.29.1. CLTX CAR-T
    • 8.29.2. CDH17 CAR-T
  • 8.30. Clade Therapeutics
    • 8.30.1. Platform Technologies
  • 8.31. Coeptis Therapeutics, Inc.
    • 8.31.1. SNAP-CAR
  • 8.32. CRISPR Therapeutics
  • 8.33. Currus Biologics
    • 8.33.1. BEAT Technology
  • 8.34. CytoMed Therapeutics Ltd.
    • 8.34.1. CAR-yDelta- T Cell
  • 8.35. Dynamic Cell Therapies, Inc.
    • 8.35.1. Platform Technology
  • 8.36. Elicera Therapeutics
  • 8.37. Galapagos NV
  • 8.38. Gracell Biotechnologies
    • 8.38.1. FasTCAR
    • 8.38.2. TruUCAR
    • 8.38.3. SMART CART
  • 8.39. EXUMA Biotech Corp.
    • 8.39.1. TMR CAR-T Technology
  • 8.40. IASO Biotherapeutics
    • 8.40.1. Technology Platforms
  • 8.41. Immuneel Therapeutics, Pvt., Ltd.
  • 8.42. ImmPACT Bio
    • 8.42.1. CD19/20 Bispecific CAR
    • 8.42.2. TGF-B
  • 8.43. Inceptor Bio
    • 8.43.1. CAR-M Therapies
  • 8.44. Interius BioTherapeutics
  • 8.45. Invectys, Inc.
    • 8.45.1. IVS-3001: Anti HLA-G CAR-T Cells
  • 8.46. Juventas Cell Therapy, Ltd.
  • 8.47. JW Therapeutics
    • 8.47.1. Carteyva (relma-cel)
  • 8.48. Galapagos NV
    • 8.48.1. Platform Technology
  • 8.49. Kite Pharma (Gilead)
  • 8.50. Kyverna Therapeutics
    • 8.50.1. "Smarter" CAR-T Cells
  • 8.51. Legend Biotech
    • 8.51.1. Carvykti
  • 8.52. Leucid Bio, Ltd.
    • 8.52.1. Lateral CAR Platform
  • 8.53. Luminary Therapeutics
    • 8.53.1. Gamma 2.0+ Platform
  • 8.54. Lupagen, Inc.
    • 8.54.1. Side CAR-T Delivery System
  • 8.55. MaxCyte, Inc.
  • 8.56. Minerva Biotechnologies
  • 8.57. Mustang Bio, Inc.
  • 8.58. Noile-Immune Biotech
    • 8.58.1. PRIME Technology
  • 8.59. Novartis AG
    • 8.59.1. Approval of Kymriah
  • 8.60. OneChain Immunotherapeutics
  • 8.61. Oncternal Therapeutics, Inc
  • 8.61. ROR1
  • 8.62. OriCell Therapeutics
    • 8.62.1. OriCAR
  • 8.63. Oxford Biomedica PLC
    • 8.63.1. Lentivector Platform
    • 8.63.2. Adeno-Associated Virus Platform
  • 8.64. Pepromene Bio, Inc.
    • 8.64.1. BAFFR CAR-T Cells
  • 8.65. PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • 8.66. Poseida Therapeutics, Inc.
    • 8.66.1. PiggyBac Platform
    • 8.66.2. CasCLOVER Platform
  • 8.67. Precigen, Inc.
    • 8.67.1. UltraCAR-T Platform
  • 8.68. Precision BioSciences
    • 8.68.1. ARCUS Gene-Editing Platform
  • 8.69. Prescient Therapeutics
    • 8.69.1. OmniCAR
    • 8.69.2. CellPryme-M
    • 8.69.3. CellPryme-A
  • 8.70. Simnova Biotherapeutics
    • 8.70.1. BiTE CAR-T Platform
  • 8.71. SOTIO Biotech B.V.
  • 8.72. TC BioPharm
    • 8.72.1. Gamma Delta T Cells
    • 8.72.2. T Cell Banks
    • 8.72.3. Co-Stim CAR-T
  • 8.73. Umoja Biopharma
    • 8.73.1. VivoVec In Vivo Gene Delivery
    • 8.73.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
    • 8.73.3. RACR/CAR In Vivo Cell Programming
    • 8.73.4. TumorTag
  • 8.74. Verismo Therapeutics, Inc.
    • 8.74.1. KIR-CAR Platform
  • 8.75. Vor Biopharma
  • 8.76. Wugen, Inc.
  • 8.77. Xenetic Biosciences, Inc.
    • 8.77.1. XBIO-020: DNase I Armored CAR-T
  • 8.78. Xyphos Biosciences, Inc.
    • 8.78.1. covertibleCAR Technology

INDEX OF FIGURES

  • FIGURE 2.1: Sales Revenues of U.S. FDA-Approved CAR-T Therapies, 2017 to 2023
  • FIGURE 3.1: Total Venture Capital (VC) Raised by CAR-T Companies Worldwide, 2014 to 2023
  • FIGURE 4.1: Total IPO Funds Raised by CAR-T Cell Therapy Companies Worldwide, 2014 to 2023

INDEX OF TABLES

  • TABLE 1.1: All Known CAR-T Fundraising Deals Worldwide, 2014 to Present (Trailing 10 Years)
  • TABLE 2.1: Number of Patients Treated with CAR-T Therapies, 2017 - 2023
  • TABLE 3.1: Venture Capital Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 4.1: IPO Funds Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 5.1: CAR-T Licensing Deals Worldwide, 2015 to Present
  • TABLE 6.1: CAR-T Collaboration Deals Signed Worldwide, 2013 to Present (Trailing 10 Years)
  • TABLE 7.1: CAR-T M&A Deals Signed Worldwide, 2015 to Present
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!